Definium Therapeutics (DFTX) Expected to Announce Quarterly Earnings on Thursday

Definium Therapeutics (NASDAQ:DFTX) is projected to announce its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Definium Therapeutics to post earnings of ($0.48) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Definium Therapeutics Price Performance

Shares of DFTX opened at $17.45 on Wednesday. The firm has a 50-day simple moving average of $15.36 and a two-hundred day simple moving average of $12.69. The stock has a market cap of $1.72 billion, a PE ratio of -8.55 and a beta of 2.57. Definium Therapeutics has a 1-year low of $4.70 and a 1-year high of $18.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.30 and a quick ratio of 3.30.

Analyst Ratings Changes

Several research firms recently weighed in on DFTX. JonesTrading assumed coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 target price for the company. Robert W. Baird set a $37.00 price target on Definium Therapeutics in a research report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Jefferies Financial Group initiated coverage on Definium Therapeutics in a research note on Thursday, January 29th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Royal Bank Of Canada raised their target price on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Definium Therapeutics has an average rating of “Buy” and an average price target of $34.20.

Insider Activity at Definium Therapeutics

In other news, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel Karlin sold 5,600 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider directly owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 42,667 shares of company stock worth $561,071. Company insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. grew its stake in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares in the last quarter. Caxton Associates LLP purchased a new stake in Definium Therapeutics during the 3rd quarter worth about $126,000. Mercer Global Advisors Inc. ADV boosted its position in shares of Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after acquiring an additional 2,079 shares in the last quarter. Finally, Scientech Research LLC purchased a new position in shares of Definium Therapeutics in the 3rd quarter valued at about $286,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.